Catumaxomab, a rat/murine hybrid trifunctional bispecific monoclonal antibody for the treatment of cancer

Current Opinion in Molecular Therapeutics

Volumn 10, Issue 3, 2008, Pages 273-284

  Shen, J ^a   Zhu, Z ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADECATUMUMAB; CATUMAXOMAB; CD20 ANTIGEN; CD3 ANTIBODY; CISPLATIN; CYTOKINE; DEXAMETHASONE; DOCETAXEL; EDRECOLOMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; EPITHELIAL CELL ADHESION MOLECULE; ERTUMAXOMAB; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; MDX 447; MELPHALAN; MONOCLONAL ANTIBODY; MT 103; MT 110; PACLITAXEL; RECOMBINANT INTERLEUKIN 2; THIOTEPA; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VB4 845;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ASCITES TUMOR; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DRUG APPROVAL; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; EROSIVE GASTRITIS; ERYTHEMA; EXTRAVASATION; FEVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEMORRHAGIC GASTRITIS; HUMAN; ILEUS; INTESTINE OBSTRUCTION; NAUSEA; NONHUMAN; OVARY CANCER; PLEURA EFFUSION; PLEURA EMPYEMA; PNEUMONIA; RASH; REVIEW; SIDE EFFECT; SKIN INFECTION; SKIN MANIFESTATION; STOMACH CANCER; STRUCTURE ACTIVITY RELATION; VOMITING;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; MICE; NEOPLASMS; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 44849130717     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. 107680 Therapy of colorectal carcinoma with monoclonal antibodies (MAb17-1A) alone and in combination with granulocyte monocyte-colony stimulating factor (GM-CSF). Mellstedt H, Frodin JE, Ragnhammar P, Masucci G, Ljungberg A, Hjelm AL, Fagerberg J, Lindemalm C, Osterborg A, Wersall P, Rieger A et al ACTA ONCOLOGICA 1991 30 8 923-931
2. 170822 First approval for Panorex. SCRIP 1995 1990 23
3. 320346 Monoclonal antibody therapy for resected Dukes' C colorectal cancer: Seven-year outcome of a multicenter randomized trial. Riethmüller G, Holz E, Schlimok G, Schmiegel W, Raab R, Höffken K, Gruber R, Funke I, Pichlmaier H, Hirche H, Buggisch P et al J Clin Oncol 1998 16 5 1788-1794
4. 397386 Annual report 1999: Medarex. Medarex Inc Annual Report 1999 December 31
5. 526850 Micromet starts MT-201 phase II trial in breast cancer. Micromet AG Press Release 2004 March 10
6. 543038 Two new trifunctional antibodies for the therapy of human malignant melanoma. Ruf P, Jaeger M, Ellwart J, Wosch S, Kusterer E, Lindhofer H INT J CANCER 2004 108 5 725-732
7. 543373 Phase I study for treatment of ovarian cancer patients with symptomatic ascites using the trifunctional bispecific antibody Removab (anti-CD3 x anti-EpCAM). Burges A, Wimberger P, Gorbounova V A, Sommer H, Schmalfeldt B, Pfisterer J, Stroehlein M, Lichinitser M R, Makhson A N, Kimmig R EUR J CANCER 2003 1 5 Abs 42
8. 543528 Immunotherapy with the trifunctional antibody Removab leads to significant elimination of tumor cells from malignant ascites in ovarian cancer: Results of a phase I/II study. Jaeger M PROC AM SOC CLIN ONCOL 2004 23 Abs 2504
9. 543564 Intraperitoneal immunotherapy of peritoneal carcinomatosis from solid tumors by trifunctional antibodies. Stroehlein M PROC AM SOC CLIN ONCOL 2004 23 Abs 2532
10. 543808 Unique GMP-conform production facilities for manufacturing trifunctional antibodies. TRION Pharma GmbH PRESS RELEASE 2000 October 9
11. 544432 High dose chemotherapy (HDCT) and hematopoietic stem cell transplantation (HPSCT) with subsequent immunotherapy in metastatic breast cancer (MBC). Final results of a phase I study. Stemmler HJ, Salat C, Lindhofer H, Menzel H, Sauer M, Untch G, Konecny G, Ledderose HJ, Kolb V, Heinemann V PROC AM SOC CLIN ONCOL 2004 23 Abs 726
12. 544726 Antitumor strategy with tri-functional antibodies. Fresenius AG PRESS RELEASE 2000 October 22
13. 544734 Fresenius receives orphan drug designation for antibody Removab to treat patients with ovarian cancer. Fresenius AG PRESS RELEASE 2004 March 19
14. 544745 Trifunctional bispecific antibody treatment of ascites due to ovarian cancer: A phase I/II study. Kimmig R, Schmalfeldt B, Burges A, Braun S, Jaeger M, Stroehlein M A, Wimberger B, Kiechle M, Heiss M M, Lindhofer H EUR J CANCER 2001 37 Suppl 3 S59
15. 544758 Innovative platform technology for cancer treatment. TRION Pharma GmbH PRESS RELEASE 2000 September 19
16. 544759 Fresenius concentrates biotechnological activities on antibody and innovative cell therapies. Fresenius AG PRESS RELEASE 2004 January 15
17. 545323 Phase I study of the novel fully human monoclonal antibody MT201, directed against epithelial cellular adhesion molecule (Ep-CAM), in patients with hormone-refractory prostate cancer (HRPC). Peters M, Dasilva A, Weckermann D, Oberneder R, Ebner B, Kirchinger P, Fetter A, Köhne-Volland R, Baeuerle P, Gjorstrup P PROC AM SOC CLIN ONCOL 2004 23
18. 550553 Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): Results of a phase I trial in patients with prostate cancer. Ko YJ, Bubley GJ, Weber R, Redfern C, Gold DP, Finke L, Kovar A, Dahl T, Gillies SD J Immunother 2004 27 3 232-239
19. 567224 Viventia's head and neck cancer drug shows phase I promise. Viventia Biotech Inc Press Release 2004 October 27
20. 572610 Infusions of T-cells armed with anti-cd3 x anti-Her2/neu bispecific antibody modulate in vivo patient immune responses in phase I clinical trials for breast and hormone refractory prostate cancers. Davol PA, Gall JM, Grabert RC, Young WB, Cummings FJ, Rathore R, Colvin GA, Elfenbein GJ, Lum LG BLOOD 2004 104:11
21. 574699 Serono licenses Micromet's anticancer agent for $10 million. Serono SA Press Release 2004 December 07
22. 581691 Fresenius - Analysts' meeting. Fresenius AG COMPANY PRESENTATION 2004 November 02
23. 583852 Effective tumor targeting: Strategies for the delivery of armed antibodies. MacDonald GC, Glover N CURR OPIN DRUG DISCOVERY DEV 2005 8 2 177-183
24. 583053 Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines. Prang N, Preithner S, Brischwein K, Goster P, Woppel W, Muller J, Steiger C, Peters M, Baeuerle PA, da Silva J BR J CANCER 2005 92:2 342-349
25. 594138 Opsonization with a trifunctional bispecific (αCD3 x αEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes. Schmitt M, Schmitt A, Reinhardt P, Thess B, Manfras B, Lindhofer H, Riechelmann H, Wiesneth M, Gronau S INT J ONCOL 2004 25 4 841-848
26. 598162 Micromet launches phase I trial combining its antibody MT201 with docetaxel for the treatment of breast cancer. Micromet AG Press Release 2005 April 27
27. 600329 Serial killing of tumor cells by cytotoxic T-cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Hoffmann, Hoffmeister, Brischwein, Brandl, Crommer, Bargou, Itin, Prang, Baeuerle A INT J CANCER 2005 115 1 98-104
28. 603337 Treatment of peritoneal carcinomatosis due to GI-tract cancer by intraperitoneal application of the trifunctional antibody catumaxomab (anti-EpcAM x anti-CD3): Results of a phase I/ II trial. Stroehlein MA, Lordick F, Ruettinger D, Gruetzner U, Menzel H, Bartelheim K, Jaeger M, Lindhofer H, Jauch K, Peschel C, Heiss MM PROC AM SOC CLIN ONCOL 2005 24 Abs 2529
29. 603363 Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab (Rexomun) in metastatic breast cancer. Kiewe P, Hasmüller S, Kahlert S, Heinrigs M, Rack B, Marmé A, Korfel A, Thiel E, Sommer H, Untch M PROC AM SOC CLIN ONCOL 2005 24 Abs 2530
30. 626802 MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Brischwein K, Schlereth B, Guller B, Steiger C, Wolf A, Lutterbuese R, Offner S, Locher M, Urbig T, Raum T, Kleindienst P et al Molecular Immunology 2005 August 31
31. 626808 Efficient tumor cell lysis by autologous, tumor-resident T lymphocytes in primary ovarian cancer samples by an EP-CAM-/ CD3-bispecific antibody. Wimberger P, Xiang W, Mayr D, Diebold J, Dreier T, Baeuerle P A, Kimmig R Int J Cancer 2003 105 2 241-248
32. 638965 Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T-cells activated with CD3 x CD19 bispecific antibodies in combination with bivalent CD28 antibodies. Bohlen H, Hopff T, Manzke O, Engert A, Kube D, Wickramanayake PD, Diehl V, Tesch H BLOOD 1993 82 6 1803-1812
33. 649407 Phase I/II study completed successfully: New antibody to treat ovarian cancer patients with symptomatic ascites (fluid accumulation in the abdominal cavity) shown to be well tolerated. Fresenius AG PRESS RELEASE 2003 September 23
34. 649501 Trifunctional antibodies, capital market day presentation. Fresenius AG COMPANY PRESENTATION 2004 January 15
35. 660025 MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors. Brischwein K, Schlereth B, Guller B, Steiger C, Wolf A, Lutterbuesea R, Offner S, Locher M, Urbig T, Raum T, Kleindienst P Mol Immunol 2006 43 8 1129-1143
36. 670716 Treatment of non-small cell lung cancer (NSCLC) patients with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3): Results of a phase I/II study. Passlick B PROC AM SOC CLIN ONCOL 2006 25 Abs 2540
37. 670779 Efficacy of intraperitoneal treatment with the trifunctional antibody catumaxomab in patients with GI-tract cancer and peritoneal carcinomatosis: A matched-pair analysis. Stroehlein MA, Gruetzner KU, Tarabichi A, Jauch KW, Bartelheim K, Lindhofer H, Von Roemeling R, Heiss MM PROC AM SOC CLIN ONCOL 2006 25 Abs 2544
38. 670791 Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3): Results of a phase I/II study. Sebastian M PROC AM SOC CLIN ONCOL 2006 25 Abs 2548
39. 672159 Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (αEpCAM x αCD3). Riesenberg R, Buchner A, Pohla H, Lindhofer H J HISTOCHEM CYTOCHEM 2001 49 7 911-917
40. 672161 Combined treatment of metastatic breast cancer (MBC) by high-dose chemotherapy (HDCT) and bispecific antibodies: A pilot study. Stemmler HJ, Salat C, Lindhofer H, Menzel H, Untch M, Kahlert S, Konecny G, Sauer H, Ledderose G, Heinemann V, Kolb HJ ANTICANCER RES 2005 25 4 3047-3054
41. 672162 Ovarian cancer - tolerability and efficacy of the trifunctional antibody Removab (anti-EpCAM x anti-CD3) after intraperitoneal application to patients with ascites: Results of a phase I/II study. Kuemper C, Burges A, Wimberger P, Gorbounova V, Sommer H, Schmalfeldt B, Pfisterer J, Jaeger M, Stroehlein M, Kimmig R J CANCER RES CLIN ONCOL 2004 130 Suppl 1 OP569
42. 672166 [T-cells activated with a trifunctional bi-specific antibody in head and neck cancer]. Removab aktivierte Lymphozyten bei Plattenepithelkarzinomen des oberen Aerodigestivtraktes. Gronau S, Schmitt M, Reinhardt P, Wiesneth M, Riechelmann H LARYNGORHINOOTOLOGIE 2005 84 11 822-828
43. 672167 Trifunctional bispecific antibody-induced tumor cell lysis of squamous cell carcinomas of the upper aerodigestive tract. Gronau SS, Schmitt M, Thess B, Reinhardt P, Wiesneth M, Schmitt A, Riechelmann H HEAD NECK: J SCI SPECIALTIES HEAD NECK 2005 27 5 376-382
44. 672168 Immunotherapy of malignant ascites with trifunctional antibodies. Heiss MM, Strohlein MA, Jager M, Kimmig R, Burges A, Schoberth A, Jauch K-W, Schildberg F-W, Lindhofer H INT J CANCER 2005 117 3 435-443
45. 680684 Pipeline. Micromet Inc COMPANY WORLD WIDE WEB SITE 2006 July 28
46. 682147 NCT00326885: Safety and efficacy study of the trifunctional antibody catumaxomab to treat recurrent symptomatic malignant ascites. Fresenius Biotech GmbH CLINICALTRIALS.GOV 2008 March 14
47. 720507 Final data from two phase II trials indicate activity of adecatumumab (MT201) in breast and prostate cancer. Serono SA Press Release 2006 October 02
48. 749975 Committee for orphan medicinal products. European Agency for the Evaluation of Medicinal Products PRESS RELEASE 2006 December 06
49. 775393 Micromet Inc reports fourth quarter and full year 2006 financial results. Micromet Inc Press Release 2007 March 16
50. 796995 Immunomonitoring results of a pivotal phase II/III study with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) in ovarian cancer patients with malignant ascites. Jaeger MJ AM SOC CLIN ONCOL 2007 43rd June 03 Abs 3020
51. 797033 Treatment of ovarian cancer patients with malignant ascites using the trifunctional antibody catumaxomab: Results of a phase II/III study. Parsons SL AM SOC CLIN ONCOL 2007 43rd June 03 Abs 5520
52. 797186 Effects of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) on proliferation and cytokine secretion of immune cells in malignant pleural effusion. Sebastian M, Jaeger M, Kiewe P, Schuette W, Wiewrodt R, Lindhofer H, Mueller B, Friccius-Quecke H, Schmittel A AM SOC CLIN ONCOL 2007 43rd June 03 Abs 3046
53. 798117 Randomized, multicenter, two-dose level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EpCAM x anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients. Belau A AM SOC CLIN ONCOL 2007 43rd June 02 Abs 5556
54. 803610 Viventia begins phase I VB6-845 epithelial cancer trial. Viventia Biotech Inc Press Release 2007 June 11
55. 813551 Secondary endpoints of phase II/III study confirm clear benefits from treatment with Removab for patients with malignant ascites. Fresenius AG PRESS RELEASE 2007 July 17
56. 821338 Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: A phase I/II study. Burges A, Wimberger P, Kumper C, Gorbounova V, Sommer H, Schmalfeldt B, Pfisterer J, Lichinitser M, Makhson A, Moiseyenko V, Kimmig R et al CLIN CANCER RES 2007 13 13 3899-3905
57. 831140 Adoptive therapy of head and neck squamous cell carcinoma with antibody coated immune cells: A pilot clinical trial. Riechelmann H, Wiesneth M, Schauwecker P, Reinhardt P, Gronau S, Schmitt A, Schroen C, Atz J, Schmitt M CANCER IMMUNOL IMMUNOTHER 2007 56 9 1397-1406
58. 834075 Characterisation of the new EpCAM-specific antibody HO-3: Implications for trifunctional antibody immunotherapy of cancer. Ruf P, Gires O, Jager M, Fellinger K, Atz J, Lindhofer H BR J CANCER 2007 97 3 315-321
59. 837451 Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): A phase I study. Sebastian M, Passlick B, Friccius-Quecke H, Jager M, Lindhofer H, Kanniess F, Wiewrodt R, Thiel E, Buhl R, Schmittel A CANCER IMMUNOL IMMUNOTHER 2007 56 10 1637-1644
60. 840679 Micromet plans German phase II trial of MT-103 for ALL. Micromet Inc Press Release 2007 October 18
61. 849021 High thermal stability is essential for tumor targeting of antibody fragments: Engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment. Willuda J, Honegger A, Waibel R, Schubiger PA, Stahel R, Zangemeister-Wittke U, Pluckthun A CANCER RES 1999 59 22 5758-5767
62. 858345 Merck Serono R&D portfolio review. Merck Serono SA Company Presentation 2007 October 24
63. 868686 EpCAM: A new therapeutic target for an old cancer antigen. Armstrong A, Eck SL Cancer Biol Ther 2003 2 4 320-326
64. 868689 Cytoplasmic tail regulates the intercellular adhesion function of the epithelial cell adhesion molecule. Balzar M, Bakker HA, Briaire-de-Bruijn IH, Fleuren GJ, Warnaar SO, Litvinov SV Mol Cell Biol 1998 18 8 4833-4843
65. 868693 The structural analysis of adhesions mediated by Ep-CAM. Balzar M, Prins FA, Bakker HA, Fleuren GJ, Warnaar SO, Litvinov SV Exp Cell Res 1999 246 1 108-121
66. 868695 EpCAM an immunotherapeutic target for gastrointestinal malignancy: Current experience and future challenges. Chaudry MA, Sales K, Ruf P, Lindhofer H, Winslet MC Br J Cancer 2007 96 7 1013-1019
67. 868696 T-cell killing of target cells induced by hybrid antibodies: Comparison of two bispecific monoclonal antibodies. Clark MR, Waldmann H J Natl Cancer Inst 1987 79 6 1393-1401
68. 868697 Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. Lindhofer H, Mocikat R, Steipe B, Thierfelder S J Immunol 1995 155 1 219-225
69. 868699 Ep-CAM: A human epithelial antigen is a homophilic cell-cell adhesion molecule. Litvinov SV, Velders MP, Bakker HA, Fleuren GJ, Warnaar SO J Cell Biol 1994 125 2 437-446
70. 868702 Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: Tumor cell-dependent T-cell stimulation and cytotoxic activity. Mack M, Gruber R, Schmidt S, Riethmüller G, Kufer P J Immunol 1997 158 8 3965-3970
71. 868703 Use of trifunctional bispecific antibodies to prevent graft versus host disease induced by allogeneic lymphocytes. Morecki S, Lindhofer H, Yacovlev E, Gelfand Y, Slavin S Blod 2006 107 4 1564-1569
72. 868704 Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Riethmüller G, Schneider-Gädicke E, Schlimok G, Schmiegel W, Raab R, Höffken K, Gruber R, Pichlmaier H, Hirche H, Pichlmayr R et al German Cancer Aid 17-1A Study Group Lancet 1994 343 8907 1177-1183
73. 868706 Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Ruf P, Lindhofer H Blod 2001 98 8 2526-2534
74. 868707 Antitumour effects of a bispecific trivalent antibody in multicellular tumour spheroids. Walz A, Mack B, Schmitt B, Gires O, Wollenberg B, Zeidler R Anticancer Res 2004 24 2B 887-893
75. 868708 Simultaneous activation of T-cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. Zeidler R, Reisbach G, Wollenberg B, Lang S, Chaubal S, Schmitt B, Lindhofer H J Immunol 1999 163 3 1246-1252
76. 868709 The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Zeidler R, Mysliwietz J, Csánady M, Walz A, Ziegler I, Schmitt B, Wollenberg B, Lindhofer H Br J Cancer 2000 83 2 261-266
77. 869896 Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3. Amann M, Brischwein K, Lutterbuese P, Parr L, Petersen L, Lorenczewski G, Krinner E, Bruckmeier S, Lippold S, Kischel R, Lutterbuese R et al Cancer Res 2008 68 1 143-151
78. 871740 Fresenius Biotech applies for the marketing authorization of the trifunctional antibody Removab for the treatment of malignant ascites. Fresenius Biotech GmbH PRESS RELEASE 2007 December 21
79. 871828 Viventia Biotech to explore strategic alternatives - reports positive pivotal phase III interim efficacy data. Viventia Biotech Inc Press Release 2008 January 29
80. 881977 Prednisolone reduces TNF-α release by PBMCs activated with a trifunctional bispecific antibody but not their anti-tumor activity. Walz A, Andratschke M, Wollenberg B, Lindhofer H, Zeidler R ANTICANCER RES 2005 25 6B 4239-4243
81. 886730 Malignant ascites: Past, present and future. Adam RA, Adam YG J AM COLL SURG 2004 198 6 999-1011
82. 886731 Immunogenicity of engineered antibodies. Hwang WY, Foote J METHODS 2005 36 1 3-10
83. 889066 Presentation at the UBS best of Germany conference. Fresenius AG COMPANY PRESENTATION 2007 September 12
84. 900195 The efficacy and safety of the trifunctional antibody catumaxomab is documented in phase II/III study. Fresenius Biotech GmbH PRESS RELEASE 2007 June 03